查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1919266

更年期肛门避孕药市场：依产品类型、适应症、剂量强度、包覆类型和销售管道划分－2026-2032年全球预测

Gengnian An Tablets Market by Product Type, Indication, Dosage Strength, Coating Type, Sales Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，更年期药丸市场价值将达到 1.9792 亿美元，到 2026 年将成长至 2.1459 亿美元，到 2032 年将达到 3.0273 亿美元，复合年增长率为 6.25%。

关键市场统计数据
基准年 2025 1.9792亿美元
预计年份：2026年 2.1459亿美元
预测年份 2032 3.0273亿美元
复合年增长率 (%) 6.25%

一个全面的框架，阐述了影响「更年期避孕药」在当代女性健康保健中的地位和普及程度的临床、监管和商业性因素。

更年期避孕药在现代女性健康照护中占据着独特的地位，它融合了传统的处方原则与现代的品管和通路。本文整合了临床证据、患者人口统计、监管介面和商业性现实，概述了影响该产品在整个医疗保健系统中的认知和使用方式的因素。透过将该疗法置于更广泛的处方行为转变、自我护理偏好以及药品价值链趋势的背景下进行分析，相关人员可以更深入地了解该产品的潜在价值提案和营运挑战。

深入探讨诊断技术的现代化、法规环境的变化以及全通路分销如何重塑女性健康药物的需求和获取途径。

在临床优先事项的整合、病患赋权和供应链现代化等因素的共同推动下，女性健康治疗领域正经历着变革性的转变。诊断准确性的提高和症状映射技术的进步正在改变临床医生区分月经和早期绝经过渡期的方式，从而促进更有针对性的治疗方案选择，并使患者能够就预后和耐受性进行更细緻的沟通。同时，远端医疗和数位化自我管理工具的兴起正在改变初级保健就诊和后续观察模式，进而影响处方笺和非处方药的使用频率。

评估近期关税调整对供应链、采购和购买动态的影响，以及医药价值链策略性供应韧性的必要性

美国2025年实施的关税调整对药品供应链产生了累积影响，尤其对依赖跨国生产、包装和零件采购的产品而言更是如此。这些关税调整提高了进口活性成分、辅料和包装材料的成本，迫使製造商重新评估筹资策略和成本结构。为此，一些公司加快了供应商多元化进程，并寻求近岸外包机会，以降低关税波动带来的风险，并缩短供应前置作业时间。

制定差异化的产品和市场推广策略，并采用综合细分框架，将临床适应症、包装、剂型、包衣和通路等因素结合起来考虑。

市场区隔的详细分析为产品契合度和上市策略如何根据通路和患者需求而变化提供了清晰且可操作的指导。基于分销管道，该市场同时涵盖非处方药 (OTC) 和处方笺药。这种双重性要求制定不同的证据策略和通讯框架，以满足消费者自我护理的动机和处方医生的期望。基于适应症，该产品的临床定位涵盖月经和更年期症状，这种区别会影响优先考虑的临床终点类型、患者援助计划的性质以及专科医生与基层医疗医生的合作模式。

区域分析重点阐述了不同的监管、分销和医疗保健系统特征如何导緻美洲、欧洲、中东和非洲以及亚太地区的不同商业化方法。

区域趋势在全球市场的监管要求、分销模式和相关人员预期方面发挥着至关重要的作用。在美洲，各国市场准入路径差异显着，尤其着重与支付方的谈判、药品目录收录、确保涵盖医院和零售商的经销经销伙伴。该地区数位药房模式也在快速普及，为直接面向消费者和患者用药依从性计画开闢了更多管道。

一份简洁的竞争分析报告，重点阐述了品质保证、证据产生和通路伙伴关係如何区分成熟製造商和灵活的新参与企业。

在各个治疗领域，竞争格局呈现出由成熟製造商、专业配药商和专注于女性健康的区域性企业组成的多元化格局。主要企业透过实证实践、品质保证和通路关係建立来脱颖而出，而小规模的新参与企业则倾向于依靠利基市场定位、柔软性的定价策略和敏捷的分销管道来参与竞争。在整个竞争格局中，一些通用的主题正在影响着企业的行为：优先考虑产品品质以满足日益严格的监管要求；重视上市后安全性监测和真实世界证据；以及投资于能够提高患者依从性和增强消费者信心的包装和剂型。

为领导者提供实际的行动步骤，以整合实证策略、供应链韧性、包装决策和多通路商业化，从而加速产品推广应用并降低风险。

为了将这项分析转化为实际优势，产业领导者可以采取一系列优先行动，以增强韧性、市场契合度和临床可信度。首先，将临床证据的生成与非处方药和处方药的双重管道结合，以确保通讯能够同时吸引消费者和处方医生。投资于能够反映症状缓解和日常功能结果的可操作临床终点，以支援所有管道的沟通。其次，实现供应商网路多元化并评估近岸外包方案，以降低关税造成的成本波动风险，缩短补货前置作业时间，从而维持服务水准并保护利润率。

调查方法概述，包括一手和二手资讯来源的整合、检验通讯协定以及对局限性的承认，以确保分析的严谨性。

本研究整合了一手和二手资料，以确保分析的严谨性和实际应用价值。一手资料包括对临床医生、药剂师、采购专业人员和行业高管进行结构化访谈，以了解临床和分销环境中的营运实践和决策标准。这些定性研究结果与监管文件、产品标籤、药物警戒总结和行业出版物进行检验，以检验临床定位和合规性方面的考虑。

综合策略重点强调了协调一致的证据产生、供应链韧性和在地化商业化对于确保持续推广应用的重要性。

总之，根年安片占据着一个策略性市场定位，它融合了既定的治疗目标与不断发展的临床实践、监管政策的明确以及多样化分销模式带来的机会。从分销管道和适应症到包装、销售管道、剂型和包衣类型等细分选择，其相互作用将决定商业性架构和成功推广所需的营运要求。那些积极主动地将实证实践与通路特定需求结合，同时增强供应链柔软性的企业，将更有利于满足监管要求，并充分利用患者和处方医生行为的变化。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型分類的更年期药物市场

  • 原厂品牌更年期缓解
    • 标准处方
    • 改进或修改后的配方
  • 学名药
    • 受监管的学名药
    • 医院配药产品
  • 组合药物产品
    • 与荷尔蒙疗法合併使用的产品
    • 与其他草药一起包装的产品
  • 特殊配方变化
    • 无糖片剂
    • 包衣片
    • 缓释片

第九章 以适应症分類的更年期药物市场

  • 月经
  • 更年期症状

第十章 以剂量强度分類的更年期避孕药市场

  • 0.6 g
  • 1.2 g

第十一章 按涂层类型分類的梅诺南丸市场

  • 薄膜涂层
  • 未涂层

第十二章 更年期市场销售管道

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 更年期药物市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 更年期市场（依群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国更年期市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章美国更年期药物市场

第十七章：中国的更年期药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Anhui Kangle Pharmaceutical Co., Ltd.
  • Beijing Tong Ren Tang Co., Ltd.
  • China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
  • Guangzhou Pharmaceutical Holdings Limited
  • Harbin Pharmaceutical Group Co., Ltd.
  • Jiangsu Kanion Pharmaceutical Co., Ltd.
  • Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  • Tianjin Tasly Pharmaceutical Co., Ltd.
  • Yunnan Baiyao Group Co., Ltd.
  • Zhejiang Kanghua Pharmaceutical Co., Ltd.
Product Code: MRR-F14BA1B34177

The Gengnian An Tablets Market was valued at USD 197.92 million in 2025 and is projected to grow to USD 214.59 million in 2026, with a CAGR of 6.25%, reaching USD 302.73 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 197.92 million
Estimated Year [2026] USD 214.59 million
Forecast Year [2032] USD 302.73 million
CAGR (%) 6.25%

A comprehensive framing of clinical, regulatory, and commercial factors that shape the positioning and uptake of Gengnian An Tablets in contemporary women's health care

Gengnian An Tablets occupy a distinctive position within contemporary women's health therapeutics, combining traditional formulation principles with modern quality controls and distribution channels. This introduction synthesizes clinical rationale, patient cohorts, regulatory touchpoints, and commercial realities that shape how the product is perceived and utilized across health systems. By situating the therapy within broader shifts in prescribing behavior, self-care preferences, and pharmaceutical supply chain dynamics, stakeholders can better appreciate the product's potential value proposition and operational challenges.

Clinically, the tablets are positioned to address symptoms related to menstrual irregularities and menopausal transition, which remain high-priority areas for both primary care and specialist gynecology. Patient demand increasingly favors treatments that balance symptomatic relief with tolerability and convenience, and that align with heightened expectations for manufacturing transparency and product traceability. From a regulatory standpoint, manufacturers are navigating evolving guidance on herbal and multi-component medicines, pharmacovigilance requirements, and quality assurance expectations that affect market access timelines and compliance costs.

Commercially, distribution strategies range from prescription pathways to over-the-counter availability, and these choices influence provider engagement, reimbursement approaches, and consumer outreach. In sum, the introduction frames Gengnian An Tablets against a multifaceted landscape where clinical utility, regulatory clarity, and adaptable commercialization strategies determine adoption and sustained uptake.

A nuanced overview of how diagnostic modernization, regulatory shifts, and omnichannel distribution are reshaping demand and access for women's health therapeutics

The landscape for women's health therapeutics is undergoing transformative shifts driven by converging clinical priorities, patient empowerment, and supply chain modernization. Advances in diagnostic granularity and symptom mapping are reshaping how clinicians differentiate irregular menstruation from early menopausal transitions, prompting more targeted therapeutic choices and more nuanced conversations with patients about expected outcomes and tolerability. Concurrently, the rise of telemedicine and digital self-management tools is changing patterns of initial care-seeking and follow-up, which in turn alters the cadence of prescriptions and OTC purchases.

Regulatory environments are also evolving, with greater emphasis on post-market safety monitoring and clearer pathways for non-conventional formulations to demonstrate consistent quality. These regulatory shifts create both opportunities and obligations for manufacturers to invest in data generation and pharmacovigilance systems. On the supply side, distribution networks are adapting to hybrid models that combine traditional hospital and retail pharmacies with growing online pharmacy channels and direct-to-consumer engagement, increasing the importance of logistics resilience and omnichannel marketing.

Financial pressures and payer scrutiny are prompting clinicians and procurement teams to prioritize interventions that demonstrate clear patient adherence and healthcare utilization benefits. As a result, companies that align clinical evidence generation with accessible delivery formats and integrated patient support will be better positioned to capitalize on changing demand patterns and to secure durable relationships with prescribers, pharmacists, and consumers.

An assessment of how recent tariff adjustments have amplified supply chain, sourcing, and procurement dynamics and necessitated strategic supply resilience across pharmaceutical value chains

The introduction of adjusted tariff measures in the United States in 2025 has had a cumulative effect on the pharmaceutical supply chain, particularly for products that rely on cross-border manufacturing, packaging, or component sourcing. These tariff adjustments have increased the cost of imported active ingredients, excipients, and packaging materials, prompting manufacturers to reassess sourcing strategies and cost structures. In response, some organizations accelerated supplier diversification and sought nearshoring opportunities to mitigate exposure to tariff volatility and to shorten supply lead times.

Importantly, these changes have amplified the operational importance of end-to-end visibility across procurement, production, and distribution. Companies that had already invested in supplier qualification programs and flexible manufacturing arrangements found it easier to adapt to incremental cost pressures. By contrast, entities more dependent on single-source international suppliers experienced margin compression and were compelled to consider price adjustments, renegotiated contracts, or reformulation where feasible.

Policy uncertainty also affected planning horizons, with procurement teams prioritizing inventory resilience and contractual flexibility over lean just-in-time models. This shift had secondary implications for working capital and storage logistics, as extended safety stocks became a practical hedging tactic. Ultimately, the cumulative impact of the 2025 tariff adjustments reinforced the strategic value of supply chain agility, robust supplier networks, and proactive commercial communication with payers and distribution partners to preserve market continuity and patient access.

An integrated segmentation framework linking clinical indications, packaging, dosage, coating, and channel considerations to inform differentiated product and go-to-market strategies

A granular view of segmentation offers actionable clarity about where product fit and go-to-market tactics should differ across channels and patient needs. Based on distribution channel, the marketplace accommodates both Otc availability and Prescription pathways, a duality that requires separate evidence strategies and messaging frameworks to address consumer self-care motivations as well as prescriber expectations. Based on indication, the product's clinical positioning spans Irregular Menstruation and Menopause Syndrome, and this distinction influences the types of clinical endpoints prioritized, the nature of patient support programs, and the specialist versus primary care engagement model.

Based on packaging format, choices between Blister Pack and Bottle formats affect adherence, supply chain economics, and patient perceptions of product quality, with blister packaging often favored where dose accuracy and portability are key. Based on sales channel, distribution must be tailored to Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy environments, each of which demands different regulatory compliance, pricing strategies, and promotional approaches. Based on dosage strength, the availability of 0.6 G and 1.2 G options creates opportunities for differentiated prescribing and stepwise titration strategies that can support adherence and personalized care. Based on coating type, Film-Coated and Uncoated variants carry distinct manufacturing considerations and patient tolerability profiles, which influence formulation development priorities and labeling recommendations.

Taken together, these segmentation dimensions form a matrix of clinical, commercial, and operational decisions. Aligning product development, evidence generation, and channel-specific engagement strategies with this segmentation matrix will enable more precise targeting of physician audiences, pharmacy buyers, and end consumers while reducing friction in the supply and prescribing pathways.

A regional analysis highlighting how divergent regulatory, distribution, and healthcare system characteristics drive distinct commercialization approaches across the Americas Europe Middle East Africa and Asia-Pacific

Regional dynamics play a decisive role in shaping regulatory requirements, distribution models, and stakeholder expectations across global markets. In the Americas, market access pathways vary substantially between national systems, with particular emphasis on payer negotiations, formulary inclusion, and distribution partnerships that can ensure both hospital and retail reach. This region also exhibits rapid adoption of digital pharmacy models, which creates additional channels for direct-to-consumer outreach and patient adherence programs.

In Europe, Middle East & Africa, regulatory complexity increases as manufacturers navigate disparate registration procedures, pharmacovigilance norms, and importation rules. The combined region demands adaptable regulatory dossiers and localized evidence packages that address country-specific safety and quality expectations, while logistics considerations are significant for reaching both urban and remote populations. Manufacturers that invest in robust local partnerships and tailored medical affairs strategies are more likely to achieve sustained penetration.

Across Asia-Pacific, heterogeneous healthcare systems and fast-growing private channels create both opportunity and complexity. This region often demonstrates strong demand for products that balance cost-effectiveness with perceived quality, and it is characterized by diverse pharmacy landscapes ranging from highly regulated hospital procurement to dynamic retail and e-commerce channels. Success across these regions depends on nuanced market entry tactics, investment in regulatory intelligence, and an ability to tailor packaging and dosing to local preferences and operational constraints.

A concise competitive analysis emphasizing quality assurance, evidence generation, and channel partnerships as differentiators among established manufacturers and agile entrants

Competitive dynamics in the therapeutic area reflect a mix of established manufacturers, specialty formulators, and regional players focused on women's health. Leading companies differentiate through evidence generation, quality assurance, and channel relationships, while smaller entrants often compete on niche positioning, pricing flexibility, or distribution agility. Across the competitive landscape, several consistent themes shape company behavior: prioritization of product quality to meet increasingly stringent regulatory expectations, emphasis on post-market safety surveillance and real-world evidence, and investment in packaging and dosing formats that support adherence and consumer confidence.

Strategic alliances and contract manufacturing partnerships remain critical for scaling production while controlling capital expenditure. Companies that demonstrate integrated capabilities across formulation development, regulatory submission, and multichannel distribution tend to achieve broader market access and faster uptake. Moreover, manufacturers that proactively invest in medical education and pharmacist engagement programs benefit from stronger recommendation rates and improved patient persistence.

Finally, the ability to adapt to regional requirements - whether through localized regulatory dossiers, tailored labeling, or flexible supply contracts - separates organizations that can sustain growth from those that face repeated market entry delays. A disciplined focus on manufacturing consistency, traceability, and transparent supply chain practices underpins competitive credibility in sensitive therapeutic segments.

Practical actionable steps for leaders to synchronize evidence strategy supply resilience packaging decisions and multichannel commercialization to accelerate adoption and reduce risk

Industry leaders can translate this analysis into practical advantages by adopting a set of prioritized actions that strengthen resilience, market fit, and clinical credibility. First, align clinical evidence generation with the dual pathway of Otc and Prescription access to ensure that messaging resonates with both consumers and prescribers; invest in pragmatic clinical endpoints that reflect symptomatic relief and day-to-day functional outcomes to support communications across channels. Second, diversify supplier networks and evaluate nearshoring options to mitigate exposure to tariff-driven cost fluctuations and to shorten replenishment lead times, thereby preserving service levels and protecting margins.

Third, tailor packaging and dosing strategies to match channel requirements and patient preferences; consider blister packs where dose tracking and portability matter most, while leveraging bottle formats for cost-efficient mass distribution. Fourth, adopt flexible commercial models for hospital, online, and retail pharmacy channels that combine targeted medical affairs outreach, pharmacist training, and digital patient-support services. Fifth, implement robust post-market safety monitoring systems and a transparent quality narrative to build trust with regulators, clinicians, and consumers alike.

Collectively, these actions will help leaders secure differentiated positioning, improve resilience against external shocks, and accelerate adoption among clinicians and patients. A focused execution plan that sequences evidence generation, supply optimization, and channel enablement will deliver the most immediate strategic return.

A methodological overview describing the primary and secondary research sources synthesis approach validation protocols and acknowledgement of limitations to ensure analytical rigor

This research synthesizes primary and secondary inputs to ensure analytical rigor and practical relevance. Primary research included structured interviews with clinicians, pharmacists, procurement specialists, and industry executives to capture operational realities and decision criteria across clinical and distribution settings. These qualitative insights were triangulated with regulatory documentation, product labeling, pharmacovigilance summaries, and trade publications to validate clinical positioning and compliance considerations.

Secondary research drew on peer-reviewed literature, clinical guidelines, and public regulatory communications to ground efficacy and safety discussions in established scientific evidence. Supply chain and commercial dynamics were informed by trade reports, logistics analyses, and published policy updates, with particular attention to recent tariff changes and their documented operational impacts. Data integrity was reinforced through cross-validation across multiple independent sources and by applying conservative interpretation where documentary evidence showed divergence.

Analytical methods emphasized segmentation mapping, scenario testing for supply disruptions, and stakeholder impact assessments to translate evidence into actionable recommendations. Limitations of the methodology are acknowledged, including variation in regional reporting standards and differences in availability of granular utilization data, and where appropriate the report outlines data gaps and recommendations for targeted follow-up studies to further reduce uncertainty.

A synthesis of strategic priorities highlighting the importance of aligned evidence generation supply chain resilience and tailored regional commercialization to secure durable adoption

In conclusion, Gengnian An Tablets occupy a strategic niche that blends established therapeutic intent with opportunities arising from evolving clinical practice, regulatory clarity, and diversified distribution models. The interplay among segmentation choices - from distribution and indication to packaging, sales channels, dosage strength, and coating type - determines the commercial articulation and operational requirements for successful deployment. Organizations that proactively align evidence generation with channel-specific needs while strengthening supply chain flexibility will be best positioned to respond to regulatory expectations and to capitalize on shifting patient and prescriber behaviors.

Recent policy and tariff adjustments have underscored the importance of supplier diversification, nearshoring evaluation, and inventory resilience as practical hedges against external shocks. Regional heterogeneity demands tailored regulatory dossiers, localized engagement strategies, and adaptable logistical planning to ensure sustained access across the Americas, Europe, Middle East & Africa, and Asia-Pacific. Competitive success will hinge on demonstrable quality, transparent safety monitoring, and targeted clinical communication that speaks directly to the priorities of prescribers and pharmacy decision-makers.

Ultimately, a coordinated approach that sequences evidence development, operational readiness, and channel-specific commercialization will produce the clearest path to durable adoption and value realization for patients, providers, and commercial stakeholders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gengnian An Tablets Market, by Product Type

  • 8.1. Original Branded Gengnian An
    • 8.1.1. Standard Formula
    • 8.1.2. Enhanced Or Modified Formula
  • 8.2. Generic Equivalent
    • 8.2.1. Regulated Generic Products
    • 8.2.2. Hospital-Compounded Equivalents
  • 8.3. Combination Regimen Product
    • 8.3.1. Co-Packaged With Hormone Therapy
    • 8.3.2. Co-Packaged With Other TCM Formulas
  • 8.4. Special Formulation Variant
    • 8.4.1. Sugar-Free Tablets
    • 8.4.2. Coated Tablets
    • 8.4.3. Extended-Release Tablets

9. Gengnian An Tablets Market, by Indication

  • 9.1. Irregular Menstruation
  • 9.2. Menopause Syndrome

10. Gengnian An Tablets Market, by Dosage Strength

  • 10.1. 0.6 G
  • 10.2. 1.2 G

11. Gengnian An Tablets Market, by Coating Type

  • 11.1. Film-Coated
  • 11.2. Uncoated

12. Gengnian An Tablets Market, by Sales Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Gengnian An Tablets Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gengnian An Tablets Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gengnian An Tablets Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Gengnian An Tablets Market

17. China Gengnian An Tablets Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anhui Kangle Pharmaceutical Co., Ltd.
  • 18.6. Beijing Tong Ren Tang Co., Ltd.
  • 18.7. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
  • 18.8. Guangzhou Pharmaceutical Holdings Limited
  • 18.9. Harbin Pharmaceutical Group Co., Ltd.
  • 18.10. Jiangsu Kanion Pharmaceutical Co., Ltd.
  • 18.11. Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  • 18.12. Tianjin Tasly Pharmaceutical Co., Ltd.
  • 18.13. Yunnan Baiyao Group Co., Ltd.
  • 18.14. Zhejiang Kanghua Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENGNIAN AN TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENGNIAN AN TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GENGNIAN AN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GENGNIAN AN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY STANDARD FORMULA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY STANDARD FORMULA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY STANDARD FORMULA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY ENHANCED OR MODIFIED FORMULA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY ENHANCED OR MODIFIED FORMULA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY ENHANCED OR MODIFIED FORMULA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY REGULATED GENERIC PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY REGULATED GENERIC PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY REGULATED GENERIC PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY HOSPITAL-COMPOUNDED EQUIVALENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY HOSPITAL-COMPOUNDED EQUIVALENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY HOSPITAL-COMPOUNDED EQUIVALENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY CO-PACKAGED WITH HORMONE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY CO-PACKAGED WITH HORMONE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY CO-PACKAGED WITH HORMONE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY CO-PACKAGED WITH OTHER TCM FORMULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY CO-PACKAGED WITH OTHER TCM FORMULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY CO-PACKAGED WITH OTHER TCM FORMULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY SUGAR-FREE TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY SUGAR-FREE TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY SUGAR-FREE TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY COATED TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY COATED TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY COATED TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY IRREGULAR MENSTRUATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY IRREGULAR MENSTRUATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY IRREGULAR MENSTRUATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY MENOPAUSE SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY MENOPAUSE SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY MENOPAUSE SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY 0.6 G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY 0.6 G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY 0.6 G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY 1.2 G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY 1.2 G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY 1.2 G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY FILM-COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY FILM-COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY FILM-COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY UNCOATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY UNCOATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY UNCOATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS GENGNIAN AN TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE GENGNIAN AN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST GENGNIAN AN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC GENGNIAN AN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN GENGNIAN AN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. GCC GENGNIAN AN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 172. GCC GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 173. GCC GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 174. GCC GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 175. GCC GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 177. GCC GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. GCC GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION GENGNIAN AN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS GENGNIAN AN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. G7 GENGNIAN AN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 202. G7 GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 203. G7 GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 204. G7 GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 205. G7 GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 207. G7 GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. NATO GENGNIAN AN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 212. NATO GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 213. NATO GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 214. NATO GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 215. NATO GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. NATO GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 217. NATO GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL GENGNIAN AN TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES GENGNIAN AN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA GENGNIAN AN TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA GENGNIAN AN TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA GENGNIAN AN TABLETS MARKET SIZE, BY ORIGINAL BRANDED GENGNIAN AN, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA GENGNIAN AN TABLETS MARKET SIZE, BY GENERIC EQUIVALENT, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA GENGNIAN AN TABLETS MARKET SIZE, BY COMBINATION REGIMEN PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA GENGNIAN AN TABLETS MARKET SIZE, BY SPECIAL FORMULATION VARIANT, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA GENGNIAN AN TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA GENGNIAN AN TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA GENGNIAN AN TABLETS MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA GENGNIAN AN TABLETS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)